SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

Minocin

CRMD·CorMedix Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market. Minocin for Injection has been FDA-approved since at least 2015 (newer formulation) and was originally approved in the 1970s.
Why 4/10
Minocin is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst for CorMedix overall is the Rezzayo sNDA PDUFA (Q1 2027), but that is a different drug. Minocin itself has no scheduled binary catalyst in the next 12 months, capping the impact score at 5.
Actionable Insight NEUTRAL

Minocin is already approved and commercialized with no upcoming binary catalyst. The next events for CRMD are Q3 2026 earnings (Nov 12, 2026) and the Rezzayo sNDA PDUFA (Q1 2027), but neither is specific to Minocin. The key thing to watch is whether the Heron Therapeutics asset acquisition (announced Nov 9, 2026) closes as expected in 2027 and how Minocin revenue trends as part of the broader Melinta portfolio.

Price Chart

Loading chart...

Executive Summary

Minocin (minocycline for injection) is an FDA-approved intravenous tetracycline antibiotic that CorMedix (CRMD) acquired through its $300M purchase of Melinta Therapeutics in September 2025. It is one of several marketed hospital products in CorMedix's portfolio, alongside DefenCath (the company's primary revenue driver) and Rezzayo. In June 2026, the Federal Circuit upheld CorMedix's Minocin patents and barred Nexus Pharmaceuticals from launching a generic version before patent expiration, protecting the product's market exclusivity. Minocin is already commercialized with no upcoming regulatory catalyst of its own; the stock's next near-term events are Q3 2026 earnings (Nov 12, 2026) and the Rezzayo sNDA PDUFA (Q1 2027).

How It Works

Minocin (minocycline) is a tetracycline-class antibiotic that stops bacterial growth by blocking protein production inside bacteria. It is given intravenously (IV) to treat serious bacterial infections, particularly those caused by susceptible strains where oral antibiotics are not appropriate.

Trial Status

Minocin is an FDA-approved, commercially marketed product. No active clinical trials were found for Minocin specifically under CorMedix. The drug's patent protection was upheld by the Federal Circuit in June 2026.

The Two-Sided Case

▲ Bull Case4
Minocin is an FDA-approved, commercially established IV antibiotic (minocycline) with patent protection upheld by the Federal Circuit in June 2026, barring Nexus Pharmaceuticals from launching a generic version before patent expiration.
The Melinta acquisition (closed Sept 2025) added Minocin and six other marketed products to CorMedix's portfolio, diversifying revenue beyond DefenCath and creating a multi-product acute-care company.
Analyst consensus is strongly bullish: 11 of 12 analysts rate Buy or Strong Buy, with a mean price target of $15.40 (190.6% upside from the $5.30 close).
CorMedix has ~$355M in cash and reaffirmed 2026 revenue guidance of $325M-$345M, with the recently announced Heron asset acquisition expected to be immediately accretive.
▼ Bear Case4
Minocin is a small part of a larger portfolio; CorMedix's main revenue driver is DefenCath, which faces a post-TDAPA reimbursement reset in 2027 that could materially reduce revenue.
The stock trades near its 52-week low ($5.10) and short-sale volume is elevated (66% on Nov 11, 2026), indicating persistent bearish sentiment.
CorMedix faces integration risk from two large acquisitions (Melinta in 2025 and Heron in 2026) and has not yet proven a second growth engine beyond DefenCath.
Generic competition risk for Minocin, while reduced by the patent win, could re-emerge if Nexus or another challenger appeals or designs around the patents.

Upcoming Catalysts

  • Q3 2026 earnings report (Nov 12, 2026, before market open)
  • Heron Therapeutics asset acquisition closing (expected 2027)
  • Rezzayo sNDA PDUFA for prophylaxis of invasive fungal diseases (Q1 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CorMedix Inc. 8-K CRMD ·Originating report

Sources · 7

Hover a chip for the title
1 streetinsider.com2 empr.com3 fiercepharma.com4 streetinsider.com5 streetinsider.com6 rttnews.com7 msn.com